Welcome to our dedicated page for Geovax Labs news (Ticker: GOVX), a resource for investors and traders seeking the latest updates and insights on Geovax Labs stock.
GeoVax Labs, Inc. (GOVX) is a clinical-stage biotechnology company whose news flow centers on vaccines for infectious diseases and therapies for solid tumor cancers. Company press releases describe active clinical development of GEO-CM04S1, a next-generation COVID-19 vaccine, and Gedeptin®, a gene-directed oncolytic therapy for head and neck cancers, along with additional programs such as the GEO-MVA Mpox/Smallpox vaccine candidate and MVA-VLP-based cancer immunotherapies.
Investors following GEO-CM04S1 news will see updates on Phase 2 trials in immunocompromised patients, chronic lymphocytic leukemia (CLL) patients, and healthy adults, as well as progress on a BARDA-funded 10,000-participant Phase 2b trial comparing GEO-CM04S1 with an approved COVID-19 vaccine. News items also cover interim data reviews, such as immune response outcomes in CLL booster studies, and broader context on the role of dual-antigen MVA-based vaccines in populations with limited responses to existing vaccines.
Oncology-related news highlights Gedeptin’s completed multicenter Phase 1/2 trial in advanced head and neck cancers and plans for a Phase 2 trial in first recurrent head and neck cancer in combination with an immune checkpoint inhibitor. Additional releases discuss preclinical data and intellectual property developments for candidates like MVA-VLP-MUC1, as well as participation in conferences and panel discussions on innovative therapies for solid tumors.
GeoVax news also includes corporate and financial updates, such as registered direct offerings and private placements of common stock and warrants, government contract revenues tied to the BARDA/Project NextGen award, and quarterly financial results. For investors and observers, the GOVX news stream provides insight into clinical milestones, regulatory and funding developments, patent allowances, and corporate presentations. Bookmarking this page allows readers to monitor how GeoVax’s vaccine and immuno-oncology programs progress through clinical stages and financing events over time.
GeoVax Labs (Nasdaq: GOVX) announced the issuance of U.S. Patent No. 11,052,148 for a vaccine targeting the Hepatitis B virus, addressing an unmet therapeutic need for over 250 million people globally. This patent supports a modified vaccinia Ankara (MVA) vector designed to generate an immune response, applicable for both prevention and treatment of chronic HBV infections. The patent arises from a collaboration with Georgia State University. The company focuses on developing human immunotherapies and vaccines for infectious diseases and cancer.
GeoVax Labs, a biotechnology firm focused on human immunotherapies and vaccines, announced participation in the Alliance Global Partners’ Virtual Healthcare Symposium on June 17, 2021. The management team will conduct 1-on-1 investor meetings during the event. GeoVax's development programs target vaccines for COVID-19, Zika, Ebola, HIV, and various cancers, utilizing an innovative MVA-VLP platform that stimulates robust immune responses akin to natural infections. For meeting requests, contact AGP Events at agpevents@allianceg.com.
GeoVax Labs (Nasdaq: GOVX) will present at the 2021 BIO Digital event on June 10, focusing on its COVID-19 vaccine and cancer immunotherapy programs. CEO David Dodd will provide insights into the company's research and development efforts. A panel discussion titled, “Vaccine Business – Five Minutes of Fame or Five-Time Oscar Winner?” will take place on June 15 at 11:05am ET, featuring Dodd. GeoVax’s vaccine platform is centered on combating infectious diseases and cancers, utilizing a Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) technology.
GeoVax Labs, Inc. (GOVX) reported significant updates in their Q1 2021 financial results, including a net loss of $1.56 million, a 163% increase from Q1 2020. Cash reserves improved to $20.8 million, bolstered by a $10.3 million stock offering and $3.2 million from warrant exercises. The company is advancing its COVID-19 vaccine, supported by a $3.2 million NIH grant, focusing on a universal vaccine to counter multiple variants. GeoVax's patent portfolio expanded to over 70 applications, enhancing its position in COVID-19 and cancer immunotherapy.
GeoVax Labs, Inc (NasdaqCM: GOVX) announced that Chairman & CEO David Dodd will participate in the Benzinga Global Small Cap Conference on May 13-14, 2021. Dodd will deliver a corporate presentation at 9:50am ET and join a panel discussion titled “Investing Post COVID – Back to the Fundamentals” at 11:50am ET on May 13. The panel will focus on healthcare investing in a post-COVID environment. Investors can also request one-on-one meetings with Dodd after the conference.
GeoVax Labs, Inc. (NASDAQ: GOVX) will report its first quarter 2021 financial results on May 6, 2021, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET, aimed at discussing financial results and company updates. The call will include a Q&A session. GeoVax is a clinical-stage biotechnology firm specializing in vaccines for infectious diseases and cancer, using a patented MVA-VLP platform. Their current developments include vaccines for COVID-19, HIV, Zika Virus, and various cancers.
GeoVax Labs (NasdaqCM: GOVX) announced a Notice of Allowance for a patent on methods to generate an immune response to Hepatitis B Virus (HBV), a critical unmet medical need affecting over 250 million people globally. The patent is co-owned with Georgia State University, emphasizing collaboration in combating chronic HBV infections. While the company's main focus remains on COVID-19 vaccines and cancer therapies, the development of an HBV treatment is part of its long-term strategy. This patent adds to GeoVax's growing portfolio of over 70 patents.
GeoVax Labs, Inc. (GOVX, GOVXW) reported its 2020 financial results, showing a net loss of $3.0 million, up from $2.4 million in 2019. Grant revenues increased from $1.2 million to $1.8 million, primarily due to U.S. Department of Defense support for the Lassa Fever vaccine. As of December 31, 2020, cash balances rose significantly to $9.9 million, compared to $283,341 in 2019, supported by a $11.2 million public offering. The company is advancing its COVID-19 vaccine and immuno-oncology programs, with several data announcements expected in the first half of 2021.
GeoVax Labs (NasdaqCM: GOVX) announces participation in the Benzinga Biotech Small Cap Conference on March 24-25, 2021. CEO David Dodd will present an overview of the company’s immunotherapy and vaccine R&D, focusing on its COVID-19 vaccine targeting various SARS-CoV-2 variants. Chief Scientific Officer Mark Newman, PhD, will join a panel on advancements in cancer immunotherapies. Investors can view the presentations by registering for the conference and can request one-on-one meetings with Dodd.
GeoVax Labs, Inc. (GOVX) has scheduled its 2020 financial results release for March 23, 2021, after market close. A conference call will follow on March 24, 2021, at 8:00 a.m. ET, to discuss these results and corporate updates. The company specializes in human immunotherapies and vaccines targeting infectious diseases and cancer, utilizing its proprietary Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) platform. Upcoming developments include preventive vaccines for COVID-19, HIV, and other diseases, with potential human clinical trials managed with the National Institutes of Health.